Mustang Bio soared nearly 480%! Announces latest positive data on CAR-T therapy MB-106
Clinical-stage biopharmaceutical company Mustang Bio closed up 476.92% on Monday, at $0.75. On the news front, Mustang Bio announced positive data from its CAR-T cell therapy MB-106 for treating Waldenstrom's macroglobulinemia in a Phase 1/2 trial. The company stated that the data showed an overall response rate of 90%, with one patient achieving complete remission after 31 months, all 10 patients in the trial had previously received treatment with BTK inhibitors. Mustang Bio noted that the CAR-T cell therapy for Waldenstrom's macroglobulinemia has not yet been approved by the U.S. Food and Drug Administration (FDA). Additionally, the company is collaborating with the Fred Hutchinson Cancer Research Center (Fred Hutch) to develop MB-106 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL)
According to the financial news app Zhitong Finance, clinical-stage biopharmaceutical company Mustang Bio (MBIO.US) saw a surge of 476.92% in its closing price on Monday, reaching $0.75. In terms of news, Mustang Bio released positive data from the Phase 1/2 trial of its CAR-T cell therapy MB-106 for treating Waldenstrom's macroglobulinemia. The company stated that the data showed an overall response rate of 90%, with one patient achieving complete remission after 31 months, all 10 patients in the trial had previously received treatment with BTK inhibitors.
Mustang Bio noted that the CAR-T cell therapy for Waldenstrom's macroglobulinemia has not yet been approved by the U.S. Food and Drug Administration (FDA). Additionally, the company is collaborating with the Fred Hutchinson Cancer Research Center (Fred Hutch) to develop MB-106 for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia (CLL)